{"id":25051,"date":"2021-09-17T12:35:23","date_gmt":"2021-09-17T10:35:23","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=25051"},"modified":"2021-11-02T16:47:30","modified_gmt":"2021-11-02T15:47:30","slug":"potencial-via-per-evitar-la-resistencia-al-tractament-dun-dels-cancers-de-mama-mes-agressius","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/potencial-via-per-evitar-la-resistencia-al-tractament-dun-dels-cancers-de-mama-mes-agressius\/","title":{"rendered":"Potencial via per evitar la resist\u00e8ncia al tractament d\u2019un dels c\u00e0ncers de mama m\u00e9s agressius"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">L&#8217;<strong>HER2 positiu <\/strong>\u00e9s <a href=\"https:\/\/ellipse.prbb.org\/ca\/joan-albanell-de-cancer-de-mama-no-nhi-ha-nomes-un\/\" target=\"_blank\" rel=\"noreferrer noopener\">un dels c\u00e0ncers de mama m\u00e9s agressius<\/a>. Per sort, existeix un tractament for\u00e7a efica\u00e7, fins al punt d\u2019aconseguir la remissi\u00f3 completa: l&#8217;antic\u00f2s monoclonal&nbsp;<strong>Trastuzumab<\/strong>. Per desgracia, fins a la meitat de les pacients HER2 positives mostren resist\u00e8ncia a aquest tractament.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ara, un estudi ha demostrat el paper d&#8217;una prote\u00efna, la&nbsp;<strong>Neuregulina<\/strong>, en la&nbsp;<strong>generaci\u00f3 d\u2019aquesta resist\u00e8ncia<\/strong>. L\u2019estudi ha estat liderat per <strong>Joan Albanell <\/strong>des de l&#8217;<a rel=\"noreferrer noopener\" href=\"http:\/\/www.imim.es\/\" target=\"_blank\">Institut Hospital del Mar d\u2019Investigacions M\u00e8diques&nbsp;(IMIM)<\/a>, i hi han participat metges, metgesses i investigadors i investigadores de l&#8217;Hospital del Mar, del CIBER d&#8217;Oncologia (CIBERONC) i d\u2019institucions italianes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La Neuregulina \u00e9s una prote\u00efna que s&#8217;uneix als receptors presents a les c\u00e8l\u00b7lules tumorals HER3 i HER2, formant un trio que confereix&nbsp;<strong>m\u00e9s capacitat de proliferaci\u00f3<\/strong>&nbsp;i <a href=\"https:\/\/ellipse.prbb.org\/ca\/descobert-un-dels-mecanismes-clau-per-entendre-la-metastasi-tumoral\/\" target=\"_blank\" rel=\"noreferrer noopener\">d&#8217;invasi\u00f3 tumoral<\/a>. El grup investigador ha observat que les pacients amb alts nivells de Neuregulina tenen menor \u00e8xit amb l&#8217;antic\u00f2s monoclonal&nbsp;<strong>Trastuzumab<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Per contra, si es combina amb un altre antic\u00f2s monoclonal, el&nbsp;<strong>Pertuzumab<\/strong>, es reverteix la situaci\u00f3 i es recuperen els nivells de resposta patol\u00f2gica completa.<\/p>\n\n\n\n<div style=\"height:33px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>\u00abL&#8217;estudi servir\u00e0 per <a href=\"https:\/\/ellipse.prbb.org\/ca\/un-model-de-prediccio-de-risc-de-cancer-de-mama-per-a-un-cribratge-mes-personalitzat\/\" target=\"_blank\" rel=\"noreferrer noopener\">optimitzar quines pacients es poden beneficiar del Pertuzumab<\/a>,&nbsp;estadificar millor quines necessiten el doble bloqueig amb Trastuzumab i Pertuzumab, i maximitzar-ne el benefici\u00bb<br><strong>Joan Albanell<\/strong>, investigador a l&#8217;IMIM i metge a l&#8217;Hospital del Mar<\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Han trobat un vincle entre els nivells de Neuregulina i la resist\u00e8ncia al Trastuzumab, un dels principals tractaments del c\u00e0ncer de mama HER2 positiu.<\/p>\n","protected":false},"author":6,"featured_media":25057,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[312,497,213,757],"new-type":[35,43],"class_list":["post-25051","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recerca","tag-cancer-ca","tag-cancer-de-mama","tag-imim","tag-tractament","new-type-noticies","new-type-recomanem"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/25051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=25051"}],"version-history":[{"count":5,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/25051\/revisions"}],"predecessor-version":[{"id":25091,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/25051\/revisions\/25091"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/25057"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=25051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=25051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=25051"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=25051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}